We are excited to continue our Molecule of the Month series. We're kicking off January with MIBG Hemisulfate
Iodine-123 metaiodobenzylguanidine (I-123 mIBG) is a radiopharmaceutical widely used in nuclear medicine for diagnosis in both cardiology and oncology [1]. Iodine-131 metaiodobenzylguanidine (I-131 mIBG) is mainly used for radiotherapy of neuroblastoma [2]. Both radiopharmaceuticals have been used intensively for decades. The precursor MIBG Hemisulfate (GMP) is available from ABX as API and ABX has a US DMF.
[1] Ming-Cheng Chang et al. Iodine-123 Metaiodobenzylguanidine (I-123 MIBG) in Clinical Applications: A Comprehensive Review. Pharmaceuticals 2024, 17, 1563.
[2] Atia Samim et al. A narrative review of 35 years of meta-[131I]iodobenzylguanidine therapy in neuroblastoma. EJC Paediatric Oncology 2024, 3, 100159.
Learn more about this compound and send us your request!
[1] Ming-Cheng Chang et al. Iodine-123 Metaiodobenzylguanidine (I-123 MIBG) in Clinical Applications: A Comprehensive Review. Pharmaceuticals 2024, 17, 1563.
[2] Atia Samim et al. A narrative review of 35 years of meta-[131I]iodobenzylguanidine therapy in neuroblastoma. EJC Paediatric Oncology 2024, 3, 100159.
Learn more about this compound and send us your request!